EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

AAV Assembled Capsids Are Produced in Cells Blocked From Cell Cycle Progression

Alaka Mullick iD, Audrey Morasse, Melanie Leclerc, Ziying Liu, Qing Yan Liu, Sonia Leclerc, Milica Momcilovic, Annie Viau, Amine A Kamen iD

Biotechnology and Bioengineering · 2026-02 · 123 (2) · 273-286

DOI: 10.1002/bit.70111 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biotechnology and Bioengineering, online erschienen am 18.11.2025. Verfasst von Alaka Mullick und 8 weiteren Autor:innen. Beteiligte Einrichtung: Human Health Therapeutics, National Research Council of Canada, Montreal, Quebec, Canada. Hauptthemen laut MEDLINE: Dependovirus, Capsid, Cell Cycle. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This work was funded by the National Research Council Canada Disruptive Technology Solutions Cell and Gene Therapy challenge program. The NRC publication numbe….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adeno‐associated virus (AAV) is a promising delivery system for gene therapy. However, current manufacturing of AAV suffers from very low yields compared to other biotherapeutics. The AAV dose per patient ranges between 10 11 and 10 15 viral genomes (vg), requiring an average of 10 to 30 L production/dose. As a consequence, production costs are prohibitive for most indications. Our recent studies revealed that only 10% of the HEK293 cells that have received the AAV encoding DNA produce assembled AAV capsids. This observation prompts the question: Why would cells that have been successfully transfected, be unable to produce AAV. To answer this question, we undertook a detailed study to characterize the two sub‐populations from the same transfection, the cells that were making assembled capsids and those that were not. We found that the two populations had distinct cell cycle profiles, with a block in cell cycle progression characterizing the producer population. RNA‐seq analysis of the two populations reveals differences in the molecular pathways impacted and provides a basis for making changes to improve productivity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DependovirusCapsidCell CycleHumansHEK293 Cells

Stichwörter der Autor:innen

AAVE1ARNA‐seqadeno‐associated viruscell cycle

Autor:innen und Institutionen

  • Human Health Therapeutics, National Research Council of Canada, Montreal, Quebec, Canada.
  • Digital Technologies Research Centre, National Research Council of Canada, Ottawa, Ontario, Canada.
  • Department of Bioengineering, McGill University, Montreal, Quebec, Canada.
  • Present Address: Gene Therapy Technical Research and Development, F. Hoffmann-La Roche AG, Basel, Switzerland.

ORCID-Profile: Alaka Mullick, Amine A Kamen

Förderung

  • This work was funded by the National Research Council Canada Disruptive Technology Solutions Cell and Gene Therapy challenge program. The NRC publication numbe…

Zitieren

APA

Mullick, A., Morasse, A., Leclerc, M., Liu, Z., Liu, Q. Y., Leclerc, S., Momcilovic, M., Viau, A., & Kamen, A. A. (2026). AAV Assembled Capsids Are Produced in Cells Blocked From Cell Cycle Progression. Biotechnology and Bioengineering, 123(2), 273-286. https://doi.org/10.1002/bit.70111

Vancouver

Mullick A, Morasse A, Leclerc M, Liu Z, Liu QY, Leclerc S, et al. AAV Assembled Capsids Are Produced in Cells Blocked From Cell Cycle Progression. Biotechnology and Bioengineering. 2026;123(2):273-286. doi:10.1002/bit.70111

BibTeX
@article{Mullick2026,
  author = {Mullick, Alaka and Morasse, Audrey and Leclerc, Melanie and Liu, Ziying and Liu, Qing Yan and Leclerc, Sonia and Momcilovic, Milica and Viau, Annie and Kamen, Amine A},
  title = {AAV Assembled Capsids Are Produced in Cells Blocked From Cell Cycle Progression},
  journal = {Biotechnology and Bioengineering},
  year = {2026},
  volume = {123},
  number = {2},
  pages = {273--286},
  doi = {10.1002/bit.70111}
}
Kostenlos starten →